A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer

Published:2018-12 Issue:12 Volume:41 Page:1193-1198
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Chen Emerson Y.,Blanke Charles D.,Haller Daniel G.,Benson Al B.,Dragovich Tomislav,Lenz Heinz-Josef,Robles Carlos,Li Hong,Mori Motomi,Mattek Nora,Sanborn Rachel E.,Lopez Charles D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference26 articles.

1. Colorectal cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer;Piedbois;J Clin Oncol,1998

3. First-line treatment of metastatic colorectal cancer: interpreting FIRE-3, PEAK, and CALGB/SWOG 80405;Elez;Curr Treat Options Oncol,2015

4. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group;Saltz;N Engl J Med,2000

5. How to integrate molecular targeted agents in the continuum of care;Kohne;Ann Oncol,2010

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis;BMC Gastroenterology;2023-08-14

2. Pathophysiology of Gastrointestinal Tract Cancers and Therapeutic Status;Phytonutrients in the Treatment of Gastrointestinal Cancer;2023-04-27

3. Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-03-30

4. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors;Nature Cancer;2023-02-09

5. A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF^V600Ecolorectal tumors;2022-10-21